Non Hodgkin's Lymphoma News and Research

RSS

The Non-Hodgkin lymphomas (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma.

Burkitt lymphoma gene expression signature identified

An international research study involving the University of Nebraska Medical Center, the National Cancer Institute and 10 other institutions has successfully identified the gene expression signature for Burkitt lymphoma.

14 Jun 2006

Is there an increased risk of other malignancies in patients with renal cell carcinoma?

There have been conflicting reports in the literature regarding the association of other malignancies with renal cell carcinoma (RCC).

14 Jun 2006

New data show Enzastaurin's activity across multiple cancer cell lines

Eli Lilly and Company's enzastaurin, an investigational, multi-targeted therapy that is currently the focus of two global Phase III clinical trials, one for the treatment of glioblastoma and one in non-Hodgkin's lymphoma

5 Jun 2006

The efficacy and safety of Rituximab in patients with active rheumatoid arthritis

Drugs aimed at suppressing inflammation-provoking cytokines--specifically those linked to T-cells--have improved the treatment of rheumatoid arthritis (RA), a chronic, inflammatory autoimmune disease. Still, the frequency of remission achieved by these biologic agents remains below 50 percent.

3 May 2006

Four subtypes of blood cancer identified

Scientists at Dana-Farber Cancer Institute and collaborators have identified four distinct genetic subtypes of multiple myeloma, a deadly blood cancer, that have different prognoses and might be treated most effectively with drugs specifically targeted to those subtypes.

26 Apr 2006

Natural killer cells and antibody-based immune function

A new drug may boost the effectiveness of a widely used treatment for patients with non-Hodgkin lymphoma (NHL), while simultaneously overcoming drug resistance in those patients.

4 Apr 2006

Lilly launches phase III trial of Enzastaurin

One of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli Lilly and Company today.

9 Mar 2006

Combination therapy improves Acquired Immunodeficiency Syndrome-Related Lymphoma outcome

Combining aggressive HIV therapy and chemotherapy significantly improves the survival rates of HIV-positive men and women treated for lymphoma, according to a new study.

27 Feb 2006

Rituximab maintenance therapy dramatically improves survival for patients with lymphoma

Two years of maintenance therapy with rituximab dramatically improves the chances of survival for patients suffering from one of the most frequent forms of lymphoma, indolent non-Hodgkin's Lymphoma (NHL).

14 Feb 2006

PET imaging has the potential to improve cancer care management

A limitation of current cancer care is the difficulty of quickly assessing how well a therapy is working. However, expanding the use of existing positron emission tomography (PET) technology can provide early and accurate assessment of a tumor's response to a particular therapy allowing physicians to better tailor a patient's treatment

7 Feb 2006

Hopes dashed for peanut allergy drug Xolair

Hopes have been dashed for a potential treatment for peanut allergies following the severe reactions suffered by two children during a clinical trial.

18 Jan 2006

The role of genes in the development of non-Hodgkin's lymphomas

An international consortium of epidemilogists - including Dr. Alexandra Nieters and Professor Nikolaus Becker of the Clinical Epidemiology Division of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) - has conducted the first ever investigation of genetic factors in the development of non-Hodgkin’s lymphoma (NHL) in a study called InterLymph.

15 Dec 2005

Cancer incidence among women has increased slightly

Overall rates of cancer death for both men and women have declined in the United States, and cancer incidence has remained stable among men. However, overall cancer incidence among women has increased slightly, according to a special article that appears in the October 5 issue of the Journal of the National Cancer Institute.

4 Oct 2005

Americans' risk of dying from cancer continues to decline

The nation's leading cancer organizations report that Americans' risk of dying from cancer continues to decline and that the rate of new cancers is holding steady. The "Annual Report to the Nation on the Status of Cancer, 1975-2002," published in the Oct. 5, 2005, issue of the Journal of the National Cancer Institute, shows observed cancer death rates from all cancers combined dropped 1.1 percent per year from 1993 to 2002.

4 Oct 2005

Possible new therapy for lymphoma and leukemia patients

Marty Holmes, a landscaper from Stockton, Calif., had never heard of a regulatory T cell before his doctor suggested that it could be the key to helping him survive his cancer.

28 Sep 2005

Drug AMD-3100 may help cancer patients who need stem cell transplants

A new drug may help cancer patients mobilize the cells necessary to restore their blood-forming system after high-dose chemotherapy, according to results from a clinical trial at the Kimmel Cancer Center at Thomas Jefferson University Hospital in Philadelphia and at other centers across the nation.

19 Sep 2005

Experimental vaccine can prime the immune system to help fight an aggressive form of lymphoma

Researchers at The University of Texas M. D. Anderson Cancer Center and the National Cancer Institute have found that an experimental vaccine can prime the immune system to help fight an aggressive form of lymphoma, even though prior therapy had eliminated virtually all of the B cells thought necessary to mount such a defense.

22 Aug 2005